Aptevo Therapeutics, Inc. logo

Aptevo Therapeutics, Inc.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on novel oncology and hematology therapeutics and was established in 2016 as a spin-off of Emergent BioSolutions Inc. (NYSE:EBS) biosciences business.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”APVO” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://aptevotherapeutics.com
Disease Focus
Development Stage
STOCK CODENASDAQ: APVO
Address
2401 4th Avenue, Suite 1050, WA 98121
Seattle
United States
Email
Contact Number
+1 888-616-0855

Aptevo Therapeutics Inc. (Nasdaq:APVO), is a clinical-stage biotechnology company focused on novel oncology and hematology therapeutics and was established in 2016 as a spin-off of Emergent BioSolutions Inc. (NYSE:EBS) biosciences business.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/aptevo-therapeutics-inc” connections=”true” suffix=””]

Aptevos proprietary ADAPTIRŽ (modular protein technology) platform develops immuno-oncology candidates that focus on redirected T-cell cytotoxicity (RTCC). ADAPTIR bispecific proteins induce target-dependent cytotoxicity at low concentrations.

Pipeline

Otlertuzumab is a monospecific ADAPTIR candidate currently in Ph II clinical development for the treatment of peripheral T-cell lymphoma.
APVO414 is a bispecific ADAPTIR candidate, targeting prostate specific membrane antigen (PSMA) and, CD3, a component of the T cell receptor complex expressed on all T cells. APVO414 redirects T cells to specifically kill PSMA expressing tumors and is being developed for metastatic castration-resistant prostate cancer.
APVO436 is a bispecific ADAPTIR candidate currently in preclinical development targeting CD123, a cell surface receptor highly expressed on several hematological malignancies.
ALG.APV-527 is a bispecific antibody candidate, partnered with Alligator Bioscience, featuring a novel mechanism of action designed to simultaneously target 4-1BB (CD137) and 5T4, a tumor antigen widely overexpressed in a number of different types of cancer.

In July 2017, Aptevo and Alligator Bioscience (Nasdaq Stockholm: ATORX), entered into an agreement to co-develop a novel immunotherapy bispecific antibody candidate, ALG.APV-527, based on Alligators first generation bispecific antibody, ATOR-1016. The new bispecific candidate was developed using Aptevos bispecific technology platform and includes proprietary binding elements generated by Alligators ALLIGATOR-GOLDŒ antibody library. Under the terms, both companies will jointly own and share equally in the development costs associated with advancing this candidate through to the end of Ph 2 clinical development. At that time, the parties may opt to out-license the candidate or continue further development separately or in partnership.